Botulinum Toxin Type A for the Prophylaxis of Chronic Daily Headache: Subgroup Analysis of Patients Not Receiving Other Prophylactic Medications: A Randomized Double‐Blind, Placebo‐Controlled Study
Abstract:Objective.-To assess the efficacy and safety of botulinum toxin type A (BoNT-A; BOTOX ® , Allergan, Inc., Irvine, CA) for the prophylaxis of headaches in patients with chronic daily headache (CDH) without the confounding factor of concurrent prophylactic medications.Background.-Several open-label studies and an 11-month, randomized, double-blind, placebo-controlled study suggest that BoNT-A may be an effective therapy for the prophylaxis of headaches in patients with CDH.Design and Methods.-This was a subgroup… Show more
“…Headache frequency diminished in over 50% of patients after two BoNT-A injection sessions, and the mean number of headache-free days per month was almost tripled (from 6 to 16 days). Furthermore, drug consumption decreased remarkably [22]. Similar results were shown by Mathew et al [23].…”
Section: Bont-a In Headache Treatmentsupporting
confidence: 86%
“…As recorded in the literature the percentage of adverse events is extremely low, BoNT-A appearing to be therefore safe and well tolerated [20][21][22][23]. In our data, only 1.6% of patients reported side effects.…”
Section: Five-year Experience With Bont-a In Cdhsupporting
“…Headache frequency diminished in over 50% of patients after two BoNT-A injection sessions, and the mean number of headache-free days per month was almost tripled (from 6 to 16 days). Furthermore, drug consumption decreased remarkably [22]. Similar results were shown by Mathew et al [23].…”
Section: Bont-a In Headache Treatmentsupporting
confidence: 86%
“…As recorded in the literature the percentage of adverse events is extremely low, BoNT-A appearing to be therefore safe and well tolerated [20][21][22][23]. In our data, only 1.6% of patients reported side effects.…”
Section: Five-year Experience With Bont-a In Cdhsupporting
“…BTNA treatment was well tolerated but high-dose BTN-A produced significantly more treatment-related AEs than did placebo. Recent studies indicate that BTN-A is no more effective than placebo at preventing infrequent migraine but is effective at preventing very frequent migraine [64].…”
“…According to the present results (similar to other published results), BoNTA can be an effective treatment method in patients with CH. The results of controlled studies on patients with chronic daily headache show that BoNTA is well tolerated and effective in reducing the frequency of painful episodes and the number of painful days (36,37 Neck muscle weakness 1 0 Table 4. Side effects…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.